This company listing is no longer active
CHCR Stock Overview
Advanzeon Solutions, Inc., through its subsidiary, Pharmacy Value Management Solutions, Inc., administers and operates a sleep apnea program known as SleepMaster Solutions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Advanzeon Solutions, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$0.018 |
52 Week Low | US$0.0001 |
Beta | 0 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | -99.44% |
3 Year Change | -99.97% |
5 Year Change | -99.93% |
Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
CHCR | US Healthcare | US Market | |
---|---|---|---|
7D | 0% | -5.9% | -2.1% |
1Y | -99.4% | -3.1% | 24.7% |
Rentabilidad frente al sector: CHCR underperformed the US Healthcare industry which returned 11.9% over the past year.
Rentabilidad vs. Mercado: CHCR underperformed the US Market which returned -14.9% over the past year.
Price Volatility
CHCR volatility | |
---|---|
CHCR Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 7.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: CHCR has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine CHCR's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1969 | n/a | Clark Marcus | https://www.advanzeon.com |
Advanzeon Solutions, Inc. Fundamentals Summary
CHCR fundamental statistics | |
---|---|
Market cap | US$11.99k |
Earnings (TTM) | -US$4.32m |
Revenue (TTM) | US$431.61k |
0.0x
P/S Ratio0.0x
P/E RatioIs CHCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CHCR income statement (TTM) | |
---|---|
Revenue | US$431.61k |
Cost of Revenue | US$234.55k |
Gross Profit | US$197.06k |
Other Expenses | US$4.52m |
Earnings | -US$4.32m |
Last Reported Earnings
Sep 30, 2020
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did CHCR perform over the long term?
See historical performance and comparison